Stem cells and the origin of gliomas: A historical reappraisal with molecular advancements

Michael L Levy1
Allen L Ho1,2
Samuel Hughes3
Jayant Menon1
Rahul Jandial4

1Division of Neurosurgery, University of California, San Diego, La Jolla, California, USA; 2Del E Webb Neurosciences, Aging and Stem Cell Research Center, The Burnham Institute for Medical Research, La Jolla, California, USA; 3Department of Neurological Surgery, Oregon Health and Science University, Portland, OR, USA; 4Division of Neurosurgery, Department of Surgery, City of Hope Cancer Center, Duarte, CA, USA

Abstract: The biology of both normal and tumor development clearly possesses overlapping and parallel features. Oncogenes and tumor suppressors are relevant not only in tumor biology, but also in physiological developmental regulators of growth and differentiation. Conversely, genes identified as regulators of developmental biology are relevant to tumor biology. This is particularly relevant in the context of brain tumors, where recent evidence is mounting that the origin of brain tumors, specifically gliomas, may represent dysfunctional developmental neurobiology. Neural stem cells are increasingly being investigated as the cell type that originally undergoes malignant transformation – the cell of origin – and the evidence for this is discussed.

Keywords: stem cells, gliomas, neural stem cells, brain tumors, cancer stem cells

Origin of brain tumors: historical insights
Over a century ago, the German pathologist Julius Cohnheim described the similarities between tumors and embryonic cells and suggested that “embryonic rests” were the source of tumors (Rather 1978). Later, the primitive cytoarchitecture and embryonic features of many malignant brain tumors was also described by Bailey and Cushing (1926). Smyth and Stern’s (1938) observed that “subependymal glia may actually be the point of origin of tumors of the thalamus.”

These earlier descriptions were further advanced in 1944, Joseph Globus and Hartwig Kuhlenbeck called attention to the subependymal cell plate in the adult brain and described this structure as one with primitive cellular composition. Based on a study with human brain tumors, they stated that “one of the most important sources for such immature embryonal residue from which neuroectodermal tumors are likely to develop under certain still unknown conditions is the subependymal plate.” (Globus 1944).

The subependymal plate was better characterized as a “mitotically active and well defined subependymal layer is present in mammalian brains throughout life” and Lewis (1968) suggested that they could be a “possible source of different histological varieties of glioma, in particular those tumors in paraventricular situation and butterfly gliomas of the corpus callosum.”

In the late 1960s Hopewell and Wright (1969) demonstrated increased glial tumors with periventricular implantation of carcinogens in rats. In the 1970s, periventricular tumors were then demonstrated to occur in the subventricular region after intraventricular inoculation with avian sarcoma viruses, with a much higher rate of tumors occurring in neonatal rats versus adult rats (Copeland et al 1975; Copeland and Bigner 1977; Vick et al 1977). A single dose of ethylnitosurea administration to pregnant rats also induced periventricular tumors in the offspring (Koestner et al 1971).

Now clear evidence exists for the “subependymal plate, as described by Gobus and Kuhlenbeck is the subventricular zone (SVZ), know to be the largest cellular region of neural stem cells (NSCs) in the adult mammalian brain. The NSCs have been characterized by Buyalla and provide the migratory neuroblasts for neurogeneis
in the olfactory bulb in rodents (Figure 1) (Sanai et al 2005). Recently, this migratory path for SVZ NSCs was also described in humans (Curtis et al 2007).

**Reappraising the prevailing theory of tumor genesis**

It has been widely accepted that cancer occurs as a consequence of genetic and epigenetic alterations in a differentiated cell. These alterations could provide a proliferative advantage and ultimately lead to uncontrolled growth and spread of the malignant cells. This theory suggests that tumors, such as gliomas, result from mutations to terminally differentiated astrocytes and oligodendrocytes that “de-differentiate” into a less differentiated phenotype (Mabon et al 1950; Doetsch et al 1999; Sakariassen et al 2007). Although the neoplastic transformation of fully differentiated glia is widely assumed to be the mechanism of gliomagenesis, this hypothesis has never been adequately tested.

**Evidence for NSC as the cell of origin**

The neurogenic zones within the human central nervous system (CNS) with their resident NSCs are considered the leading candidates for transformation leading to brain tumors. Specifically mitotically active cells (NSCs and their direct progeny, transit amplifying cells) are the cells that have the greatest probability of being the brain tumor cell of origin.

**NSCs and gliomas share histological and biological similarities**

Gliomas have long been described by pathologists for their remarkable cellular heterogeneity, and in fact the most aggressive and malignant glioma (glioblastoma multiforme) was termed based partly on the histological diversity comprising this tumor, hence “multiform.” A transformed NSC could provide this cellular landscape due to their multilecellular diversity (ability to differentiate into the cell types that constitute their respective germ line). Mixed cell gliomas exist, such as oligoastrocytomas, and have both oligodendrocytes and astrocytes (Valtz et al 1991) and could be independent transformation of two differentiated cells, as suggested by the dedifferentiation theory of tumor genesis. More plausible would be the transformation of a single, bipotential progenitor cell such as a NSC or a transit amplifying cell (Chekenya and Pilkington 2002). These mixed cell gliomas also exhibit loss of heterozygosity on chromosomes 1p and 19q in both the astrocytic and oligodendrocytic components (Kraus et al 1995), suggesting that, in oligoastrocytomas, the astrocytes and oligodendrocytes comprising the tumor have a shared cell of origin.

Further, many glioma cells are undifferentiated, and lack expression of differentiated cell markers, as well as demonstrate staining with markers for nestin. Nestin expression is one hallmark feature of NSCs (Dahlstrand et al 1992; Tohyama et al 1992), and has become a reliable marker of NSCs (Lendahl et al 1990). Gliomas and NSCs also exhibit characteristic overlapping behavior (Table 1) (Sanai et al 2005), such as high motility, association with vasculature and white matter tracts (Shoshan et al 1999; Doetsch et al 2002; Palmer et al 2000).

**NSCs more likely to accumulate oncogenic mutations**

Accumulation of oncogenic genetic hits by cells is an infrequent stochastic event that most likely takes considerable time to result in transformation. NSCs, defined by their ability to self renew are both mitotically active and exist during the lifetime of the individual.
Stem cells and the origin of gliomas


<table>
<thead>
<tr>
<th>Characteristics intrinsic to neural stem cells and gliomas.</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>High motility</td>
<td></td>
</tr>
<tr>
<td>Diversity of progeny</td>
<td></td>
</tr>
<tr>
<td>Robust proliferative potential</td>
<td></td>
</tr>
<tr>
<td>Association with blood vessels</td>
<td></td>
</tr>
<tr>
<td>Association with white-matter tracts</td>
<td></td>
</tr>
<tr>
<td>Immature expression profiles</td>
<td></td>
</tr>
<tr>
<td>Nestin expression</td>
<td></td>
</tr>
<tr>
<td>EGF-receptor expression</td>
<td></td>
</tr>
<tr>
<td>PTEN expression</td>
<td></td>
</tr>
<tr>
<td>Hedgehog pathway activity</td>
<td></td>
</tr>
<tr>
<td>Telomerase activity</td>
<td></td>
</tr>
<tr>
<td>Wnt pathway activity</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: EGF, epidermal growth factor.

of the animal, allowing them to potentially accumulate the necessary multiple mutations for tumor formation. Accordingly, the cellular origin of gliomas would most likely occur from the proliferative zones in the mammalian CNS such as the SVZ contain at least two types of mitotically active cells: NSCs and transit amplifying cells (TACs) (Seri et al 2004). Although TACs exist only briefly and then differentiate, their total cellular compartment is significantly larger than NSCs and total number of global number of divisions during their relatively short lifespan are comparable to NSCs that exist throughout life yet are less mitotically active (Figure 2) (Vescovi et al 2006).

Cancer stem cells

Approximately 150 years ago, pathologists Rudolph Virchow and Julius Cohnheim suggested there were histological similarities between the developing fetus and certain cancers (such as teratocarcinomas) and that both tissues have the capacity to differentiate and proliferate. This “embryonal-rest hypothesis” is the historical version of today’s cancer stem cell (CSC) hypothesis (Huntly and Gilliland 2005). As defined at the American Association for Cancer Research workshop on cancer stem cells: cancer stem cells are cells that (1) self renew and (2) re-supply the tumor with the various lineages of cells of which it is comprised. Self renewal can only be defined experimentally by the ability to recapitulate the generation of a continuously growing tumor or tumor initiation cell (Figure 3) (Clarke et al 2006; Lee and Herlyn 2007).

The original work establishing the CSC model was based on the hematopoietic system. Evidence for leukemia-CSCs was first reported in 1994 when Lapidot and colleagues isolated a rare population of CD34+CD38− cells from patients with acute myeloid leukemia. Infusion of these CD34+CD38− cells into severe combined immune-deficient mice resulted in leukemic blast generation; however, more differentiated cells (CD34+ CD38+) did not generate leukemia (Lapidot et al 1994; Al-Hajj et al 2003; Buzzeo et al 2007). On a molecular level, CSCs share properties with normal stem cells. They have similar markers and signaling pathways, respond to environmental cues, as well as telomerase activity, apoptosis clearance and increased membrane transporter activity (Sakariassen et al 2007).

The first report of cells with stem-like properties in brain tumors was by Ignatova and colleagues (2002) where surgical specimens of glioblastoma multiforme were shown to have
clonogenic neurosphere-forming cells that expressed both neuronal and glial markers upon differentiation (Figure 4) (Ignatova et al 2002; Vescovi et al 2006). Subsequently, the Dirks group demonstrated CSC in brain tumors by transplantation of CD133+ or CD133− populations into immunodeficient mice. With as few as 100 CD133+ cells from the primary tumor, a new phenocopy of the tumor could be created in the transplanted mice; and unsorted or CD133− primary tumor cells were unable to cause de novo tumor generation. As part of what has come to define CSCs—self-renewal capacity—was also shown by confirming the ability of serially transplanted CD133+ cells to recapitulate the original tumor (Singh et al 2004; Buzeeo et al 2007). These findings established the presence of brain tumor stem cells (BTSCs), cells which can differentiate into the neural lineages, and exhibit self-renewal as demonstrated by recapitulation of primary tumors with serial transplantation. This has been shown for other types of brain tumors as well (Merkle et al 2004; Taylor et al 2005). The existence of these BTSCs adds further evidence toward the NSCs origin of gliomas by confirming that different brain tumors contain transformed, undifferentiated neural precursors that respond to the same mitogens that activate adult NSCs (Vescovi et al 2006). Second, they indicate that tumor stem-like cells possess some of the molecular features of NSCs. Third, BTSCs, through asymmetric division, could generate a BTSCs and a progenitor cell, the latter of which may migrate away to either form or contribute to the tumor mass (Vescovi et al 2006, Berger et al 2004).

Gliomas and NSCs have common regulatory pathways

Neural stem cells and progenitor cells have activated cellular pathways, such as pro-mitotic genes, telomerase activity, and anti-apoptotic genes. This innate capacity overlaps with the mechanisms underlying tumor initiation, progression, or both. Thus, NSCs may require the least amount of mutations to become transformed.

1. EGFR expression is up-regulated in primary glioblastoma multiforme and transiently dividing progenitors (type C cells) (Mellinghoff et al 2005).
2. Fibroblast growth factors (FGFs) are involved in tumor proliferation and angiogenesis (Joy et al 1997; Auguste et al 2001) and also shown to regulate NSC proliferation and cell fate (Vescovi et al 1993; Grittì et al 1996; Palmer et al 1999).
3. Notch receptors and signaling is involved in NSC renewal (Hitoshi et al 2002; Shen et al 2004) and related to proliferative capacity of gliomas (Purow et al 2005).
4. PTEN is a tumor suppressor with an important function in the control of proliferation of neural stem cells and progenitor cells in vivo and in vitro (Baker and McKinnon 2004; Groszer et al 2001; Reya and Clevers 2005). PTEN is inactivated in glioblastomas (Rasheed et al 1999; Wechsler-Reya and Scott 2001) and its preservation in glioblastoma multiforme is clinically favorable (Mellinghoff et al 2005).
5. The Wnt-catenin pathway regulates adult neurogenesis (Chenn and Walsh 2003; Lie et al 2005) modulating its activity may increase glioma cell growth (Roth et al 2000). Recent experiments have also highlighted the increased ability of progenitor cells to be transformed versus differentiated cell types. If epidermal growth factor receptor (EGFR) is transfected into transgenic Ink4a-Arf−/− mouse (lacking genes for cell-cycle arrest) neural stem cells, the cells lead to glioma formation (Bachoo et al 2002). This contrasted with similar manipulation of differentiated mouse astrocytes. Further, if the undifferentiated mouse astrocytes were transfected with platelet-derived growth factor (pdgf) transgene and converted to a less differentiated state, they showed increased oncogeticity (Dai et al 2001; Bachoo et al 2002; Uhrbom et al 2002).

Mouse models of gliomas for investigation of glioma origin

Mouse models of gliomas are available and offer a unique opportunity to investigate tumor origin. These models,
unlike glioma models in *Drosophila* and *C. elegans*, recapitulate the human pathology in terms of such characteristic structures as pleomorphic nuclei, diffusely infiltrative margins, secondary structures of Scherer, necrosis with pseudopalisading tumor cells, and microvascular proliferation. Xenograft models fail to phenocopy the classic histopathological features and are not an option for elucidating developmental mechanisms. Ultimately, these models of spontaneous tumor development and progression allows for the potential identification of novel mechanisms for tumorigenesis (Ding et al. 2001).

**Relevance of identifying the glioma cell of origin**

Brain tumor classification with current histological criteria fails to accurately categorize patients as many patients with similar grade brain tumors have highly variable clinical outcomes. Clearly, this classification is one that at a minimum...
needs molecular modifiers. Defining the cell of origin, and confirming whether NSCs are indeed the cell of origin would improve not only glioma classifications, but also detection and treatment. The differential antigenic and molecular attributes of NSCs responsible for tumorigenesis could be exploited to target malignant cells prior tumor progression to clinical presentation. Indeed, defining cell of origin could help expand the concept of chemoprevention: targeting cells in the pre-morbid state.

**Disclosure**
The authors report no conflicts of interest in this work.

**References**


Stem cells and the origin of gliomas


